Replies to post #1829 on ProtoKinetix Inc (PKTX)

[sunspotter]

"Mr Smith is not only the new CEO but the largest shareholder of PKTX so he has a huge vested interst in making sure the company does well."

Or at least in ramping up the volume so he can dump some of his free shares onto his unsuspecting marks.

It's strange phenomenon with these penny stock scams like PKTX:

Up until the day they leave the company, the CEO is a hero battling against huge odds to make a success of the remakable technology the company has.

The day after they leave, it turns out that they were probably the principal reason for the lack of success of the company so far, and now that they've gone, the brakes will come off and the company will career willy-nilly into a bright new future.

Yeah, right.

[Past and present]

***PKTX.. PROTOKINETIX, INCORPORATED.
9176 South Pleasants Highway
St. Marys, WV 26170

..ProtoKinetix Announces New President and Chief Executive Officer

February 23, 2015

...ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix") announces that a cease trade order issued by the British Columbia Securities Commission was revoked effective as of the date of this news release.

..In connection with the revocation, the Company also announces that it has received and accepted the resignation of Mr. Ross Senior as a Director, President and Chief Executive Officer of the Company effective as of February 19, 2015. Mr. Clarence E. Smith has been appointed as the Company's new President and Chief Executive Officer.

..ProtoKinetix further announces that it has moved its head office to 9176 South Pleasants Highway, St. Marys, West Virginia, USA 26170.

About ProtoKinetix

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.
ON BEHALF OF THE BOARD OF DIRECTORS
PROTOKINETIX, INCORPORATED
Clarence E. Smith
President and Chief Executive Officer
For further information, please contact:
Clarence E. Smith, President & Chief Executive Officer
Telephone: [phone]
Email: [e-mail]